Drug Trial Radar · NCT06023589
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
231
Planned (sponsor's estimate)
Start
Aug 24, 2023
Primary completion
May 31, 2028
Study completion Aug 23, 2030
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Amgen
- First posted
- Sep 5, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 5 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the efficacy and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled corticosteroids (ICS) and at least one additional asthma controller medication with or without oral corticosteroids.
Conditions
- Asthma
Interventions
TezepelumabBiological
Participants will be receiving subcutaneous injection of tezepelumab
PlaceboOther
Participants will be receiving subcutaneous injection of matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized severe asthma exacerbation rate (AAER)Time frame: From Baseline to Week 52
Locations
147 sites in 22 countries. Site status is shown where the registry gives one.
Research Site
Montgomery, Alabama · Recruiting
Research Site
Phoenix, Arizona · Recruiting
Research Site
Little Rock, Arkansas · Withdrawn
Research Site
La Jolla, California · Active not recruiting
Research Site
Long Beach, California · Recruiting
Research Site
Orange, California · Withdrawn
Research Site
San Diego, California · Recruiting
Research Site
Atlanta, Georgia · Recruiting
Research Site
Savannah, Georgia · Terminated
Research Site
Baltimore, Maryland · Recruiting
Research Site
Boston, Massachusetts · Recruiting
Research Site
Boston, Massachusetts · Recruiting
Research Site
Ann Arbor, Michigan · Terminated
Research Site
Detroit, Michigan · Recruiting
Research Site
Northfield, New Jersey · Recruiting
Research Site
Hawthorne, New York · Recruiting
Research Site
Schenectady, New York · Withdrawn
Research Site
Staten Island, New York · Recruiting
Research Site
Chapel Hill, North Carolina · Recruiting
Research Site
Cincinnati, Ohio · Recruiting
Research Site
Cleveland, Ohio · Recruiting
Research Site
Toledo, Ohio · Recruiting
Research Site
Oklahoma City, Oklahoma · Recruiting
Research Site
Columbia, South Carolina · Withdrawn
Research Site
Coppell, Texas · Terminated
Research Site
Dallas, Texas · Recruiting
Research Site
Frisco, Texas · Withdrawn
Research Site
Houston, Texas · Recruiting
Research Site
San Antonio, Texas · Recruiting
Research Site
Temple, Texas · Withdrawn
Research Site
Buenos Aires, Argentina · Recruiting
Research Site
Buenos Aires, Argentina · Recruiting
Research Site
Buenos Aires, Argentina · Recruiting
Research Site
CABA, Argentina · Terminated
Research Site
Florida, Argentina · Recruiting
Research Site
Lanus, Argentina · Recruiting
Research Site
Lobos, Argentina · Recruiting
Research Site
Mendoza, Argentina · Recruiting
Research Site
Quilmes, Argentina · Terminated
Research Site
Rosario, Argentina · Recruiting
Showing 40 of 147 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.